Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists. Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management! Faculty Sven Francque (Moderator)Willem...

Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health. Faculty Aleksander Krag (Moderator)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)Debbie Shawcross (Faculty)All EASL Studio Podcasts are available on EASL Campus.

Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition. This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and...

With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice. Faculty Tom Lüdde (Moderator)Christoph Roderburg (Faculty)Anna Saborowski (Faculty)Arndt Vogel...

This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions. Faculty Palak Trivedi (Moderator)Amanda Ricciuto (Faculty)Marianne Samyn (Faculty)Christoph Schramm (Faculty)This EASL Studio is...

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis. Faculty Thomas Reiberger (Moderator)Juan Gonzalez-Abraldes (Faculty)Elisa Pose (Faculty)Jonel Trebicka (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input...

In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases. Faculty Zobair Younossi (Moderator)Laurent...

In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases. Faculty Aleksander Krag (Moderator)Juan Pablo Arab (Faculty)Alexandre Louvet (Faculty)Maru Rinella (Faculty)Related episodes: EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E8: The central role of alcohol and...

Join the faculty as they take a deep dive into hepatitis delta (HDV) to: Shed light on the controversies surrounding this disease.Share their perspectives on the latest and most hotly debated recommendations.Discuss how these new recommendations will shape the future of research and patient care.Faculty Thomas Berg (Moderator)Maurizia Brunetto (Faculty)Ohad Etzion (Faculty)Related episodes: EASL Studio S2E3: Interview with Stephan Urban – From bench to bedside: Process of developing the first...

During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life. This episode was scheduled according to the international calendar for the World Food Day (16 October) Faculty Shira Zelber Sagi (Moderator)Riccardo Dalle Grave (Faculty)Giulio Marchesini (Faculty)Related episodes EASL Studio S4E8: The central...

This episode delves into the pervasive yet seldom-discussed issue of burnout, particularly prevalent in high-pressure fields like clinical medicine and competitive research. Fuelled by relentless ambition and a fear of falling short, professionals push themselves to the limit, often neglecting their own well-being. As the world grapples with a confluence of challenges including the ongoing pandemic, climate crisis, and geopolitical tensions, the need for self-care becomes more pressing than...

In this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article: Is the introduction of metabolic risk factors (MRF) for the definition of MASLD justified?What are the main issues regarding the measurement and thresholds for MRFs?Is the introduction of the MetALD category clinically justified?Is it necessary to worry about MRFs in a patient drinking increased or excessive amounts of alcohol and if yes, how should these be...

This EASL Studio episode covers the highlights of the SLD Summit 2023, including: Physiopathological mechanismProblems encountered in the cirrhotic stage in SLDNovelties about liver biopsiesFaculty Sven Francque (Moderator)Quentin Anstee (Faculty)Frank Tacke (Faculty)Maja Thiele (Faculty)Related episodes EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio Live from EASL Congress 2023: Steatotic liver disease global...

Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). HEV infections are among the most common causes of acute hepatitis worldwide. 2 different settings: HEV genotypes 1 and 2 cause primarily in water-born outbreaks inn resource-limited settingsHEV genotypes 3 and 4 have emerged as porcine zoonoses in middle and high-income areas, including EuropeThis Studio focuses on Zoonotic Hep E, especially HEV Genotype 3 infection and discusses recent...

Thirty percent of the global population have too much fat in their liver. The big question is: are they really sick when most will not end up with liver disease? This episode discusses: How should they be assessed and by whom?What does this mean to healthcare systems?Are there downsides to systematic screening?Faculty Aleksander Krag (Moderator)Alina Allen (Faculty)Manal El-Sayed (Faculty)Ian Rowe (FacultyRelated episode EASL Studio Live from EASL Congress 2023: Steatotic liver disease global...

This #EASLStudio JHEP Live discusses the newly released EASL Clinical Practice Guidelines on Acute-on-chronic liver failure (ACLF). In particular: ICU admission criteria for patients with ACLFTreatment of infection and antibiotic selectionLiver supportLiver transplantation for ACLF: Sarcopenia and frailtyFaculty Richard Moreau (Moderator)Rajiv Jalan (Faculty)Constantine Karvellas (Faculty)Rakhi Maiwall (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is presenting the work of international liver societies to beat liver diseases. Faculty Thomas Berg, EASL (Moderator)Marcelo Silva, ALEH (Faculty)Norah Terrault, AASLD (Faculty)Manal El-Sayed, SOLDA (Faculty)Shiina Shuichiro, APASL (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Closing was live broadcast during the EASL Congress 2023 and discusses the future of hepatology. Faculty Thomas Berg (Moderator)Aleksander Krag (Moderator)Tobias Böttler (Faculty)Debbie Shawcross (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Good Morning Vienna was live broadcast during the EASL Congress 2023 and is presenting the highlights of liver cancer research at the congress. Faculty Jean-Charles Nault (Moderator)Josep Llovet (Moderator)Jessica Zucman-Rossi (Faculty)Bruno Sangro (Faculty)Matthias Pinter (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is covering practice changing following data presented during the congress. Faculty Virginia Hernández-Gea (Moderator)Ahmed Elsharkawy (Moderator)Maru Rinella (Faculty)Maria Reig (Faculty)Nancy Reau (Faculty)Verena Keitel (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the nomenclature change for steatotic liver disease. Faculty Aleksander Krag, EASL (Moderator)Philip Newsome, EASL (Faculty)Maru Rinella, AASLD (Faculty)Graciela Castro-Narro, ALEH (Faculty)Mohamed El-Kassas, SOLDA (Faculty)Robert Mitchell-Thain, LPI (Faculty)Lorraine Stiehl, ALF (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the newly released EASL policy statement on alcohol harm and related liver diseases. The document aims to highlight the extensive harm resulting from alcohol consumption and shine a light on the effective, yet underused, harm reduction policies available to European countries. Faculty Frank Murray Ireland (Moderator)Maria Buti (Moderator)Thomas Babor (Faculty)All EASL Studio Podcasts are available on...

In honour of International NASH Day, the final episode of EASL Studio season 4 is shedding light on non-alcoholic steatohepatitis (NASH), a disease with increasing global prevalence but low awareness. Faculty Zobair Younossi (Moderator)Alina M. Allen (Faculty)Sven Francque (Faculty)Vincent Wong (Faculty)Shira Zelber-Sagi (Faculty)All EASL Studio Podcasts are available on EASL Campus.

Non-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available. This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular: ARO-HSD, an HSD17β13 inhibitor.PXL065 under evaluation in the DESTINY-1 trial.The investigation of an FXR agonist in fibrotic NASH as part of the LIVIFY trial.Faculty Prof....

Clinical evidence indicates that cigarette smoking negatively impacts the incidence and severity of fatty liver disease, fibrosis progression, hepatocellular carcinoma development, and the outcomes of patients with advanced liver disease. The underlying mechanisms are complex and involve different pathophysiological pathways including oxidative stress and oncogenic signals. To coincide with World No Tobacco Day, 31 May, this EASL Studio discusses some of the pathophysiological mechanisms that...